- Raw materials
- Antifungals
- Chlorfenson
Chlorfenson API Manufacturers & Suppliers
0 verified results
Commercial-scale Suppliers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Total market transparency
Supplier trade data access
Buyer / supplier flow comparison
Chlorfenson | CAS No: 80-33-1 | GMP-certified suppliers
A medication that targets fungal nail infections, offering a topical treatment option aimed at reducing systemic risks associated with current antifungal therapies.
Therapeutic categories
Primary indications
- Investigated for use/treatment in fungal infections
Product Snapshot
- Chlorfenson is an oral small molecule formulation
- It is investigated primarily for antifungal therapeutic applications
- The compound is currently in an investigational status and not yet approved by major regulatory agencies
Clinical Overview
The principal clinical indication of Chlorfenson focuses on fungal infections of the nails, aiming to address the significant unmet need for effective topical therapies in onychomycosis. Current treatment options for extensive nail involvement—typically when over 50% of the nail is affected—rely predominantly on systemic antifungal agents, which carry risks of notable adverse effects. Chlorfenson is formulated as a topical solution applied once daily to the affected areas, with treatment durations spanning from three to six months.
While detailed pharmacodynamic parameters have not been specified, the presumed mechanism of action involves the topical application of the arylsulfonate ester contributing to antifungal activity localized within the nail matrix and surrounding tissues. This localized action potentially reduces systemic exposure and mitigates systemic toxicity compared to oral antifungals.
Pharmacokinetic information, including absorption, distribution, metabolism, and excretion (ADME) characteristics, has not been disclosed in the available data, reflecting its investigational status.
Safety and toxicity profiles remain under evaluation in clinical studies; however, the topical route of administration suggests a potentially improved safety margin relative to systemic therapies currently in use for this indication.
As Chlorfenson is under investigation and not yet approved for commercial use, sourcing considerations for the API should prioritize suppliers with demonstrated expertise in manufacturing benzenesulfonate esters under stringent quality control conditions. Comprehensive quality assessments including purity, polymorphic form, and stability should be rigorously documented to ensure consistency for clinical development.
Identification & chemistry
| Generic name | Chlorfenson |
|---|---|
| Molecule type | Small molecule |
| CAS | 80-33-1 |
| UNII | LW65NJ3YWV |
| DrugBank ID | DB05377 |
Pharmacology
| Summary | Chlorfenson is a topical antifungal agent targeting fungal pathogens responsible for nail infections. It acts by disrupting fungal cell processes to inhibit growth and promote clearance of infection. The compound is designed for localized treatment of onychomycosis, aiming to reduce reliance on systemic therapies. |
|---|---|
| Mechanism of action | Chlorfenson is a topical solution applied once-daily on affected nails during treatment periods of 3-6 months. In pilot studies, Chlorfenson has shown promising results and provides important benefits compared to existing treatment alternatives. There is a significant need for more efficacious topical treatments. For more severe cases of the disease where more than 50% of the nail is affected, the only available options are oral anti-fungals which are associated with a certain risk for severe side effects. |
Formulation & handling
- Chlorfenson is a small molecule with low aqueous solubility, indicating the need for solubilization strategies in oral formulations.
- Its moderate molecular weight and hydrophobicity suggest formulation approaches to enhance bioavailability.
- Stability and handling should consider benzenesulfonate ester chemical sensitivity, particularly to hydrolysis under acidic or basic conditions.
Regulatory status
Chlorfenson is a type of Antifungals
Antifungals are a vital category of pharmaceutical active pharmaceutical ingredients (APIs) designed to combat fungal infections. These medications are developed to target and eliminate fungi, including yeasts and molds, which can cause a range of diseases in humans and animals.
Antifungals work by interfering with specific components or processes essential for fungal growth and reproduction. They may inhibit the synthesis of fungal cell walls or disrupt the production of ergosterol, a crucial component of fungal cell membranes. By targeting these key mechanisms, antifungal APIs effectively hinder the growth and spread of fungal infections.
The diversity within the antifungal category is reflected in the various classes of antifungal APIs available. Azoles, polyenes, echinocandins, and allylamines are common classes of antifungals. Each class exhibits unique mechanisms of action and targets specific types of fungi. This diversity enables healthcare professionals to tailor treatment plans to the specific fungal infection, optimizing therapeutic outcomes.
Antifungal APIs find application in various pharmaceutical formulations, including oral medications, topical creams, ointments, and intravenous solutions. They are crucial for the treatment of common fungal infections like athlete's foot, ringworm, vaginal yeast infections, and oral thrush. Additionally, antifungals play a crucial role in managing serious systemic fungal infections that can pose significant health risks, especially in immunocompromised individuals.
Overall, antifungal APIs are indispensable tools in the fight against fungal infections, offering effective treatment options and improving the quality of life for patients suffering from these conditions. With ongoing research and development, the antifungal category continues to evolve, providing innovative solutions to combat the ever-changing landscape of fungal pathogens.
